Which is better, Fruquintinib or Bevacizumab?

Fruquintinib) and bevacizumab (Bevacizumab) are both drugs used to treat certain cancers. They belong to different drug classes and have different mechanisms of action and application scenarios. The choice of which drug is more appropriate depends on the patient's specific situation, the type of tumor and the recommendations of the doctor.

1. Mechanism of action:

Fruquintinib: It is a drug that targets the vascular endothelial growth factor receptor (VEGFR). It mainly blocks the blood supply of tumors and slows down the growth of tumors by inhibiting angiogenesis.

Bevacizumab: Bevacizumab is an anti-vascular endothelial growth factor (Anti-VEGF) drug that inhibits the action of VEGF and prevents the formation of new blood vessels, thereby slowing down the growth of tumors.

2. Indications:

Fruquintinib: It is often used to treat digestive system tumors such as advanced colorectal cancer and gastric cancer as part of maintenance therapy.

Bevacizumab: It is used in a variety of cancers, including colorectal cancer, breast cancer, non-small cell lung cancer, etc. In some cases, it may also be used with chemotherapy drugs.

3. Combination treatment:

Fruquintinib: Usually used as monotherapy for maintenance therapy. In some cases, it may be used in conjunction with other treatment modalities.

Bevacizumab: It can be used as a monotherapy or in combination with other anticancer drugs, such as chemotherapy drugs, depending on the tumor type and treatment regimen.

4. Medicine administration:

Fruquintinib: It is generally an oral drug that is convenient for patients to treat at home.

Bevacizumab: It is usually given by intravenous injection and needs to be given in a medical setting.

5. Different side effects:

Fruquintinib: Common side effects include hand-foot syndrome, hypertension, proteinuria, fatigue, etc.

Bevacizumab: Common side effects include high blood pressure, bleeding, blood clotting problems, proteinuria, fatigue, etc.

6. Personalized treatment:

Fruquintinib: It is suitable for some patients with advanced colorectal cancer and gastric cancer, especially those who are resistant or intolerant to other treatments.

Bevacizumab: Applicable to a variety of cancer types, but the specific treatment plan needs to be determined based on the patient's condition and the doctor's recommendations.

In actual treatment, doctors will develop an individualized treatment plan based on the patient's specific situation, tumor type and course, as well as drug side effects and other factors. Sometimes, these two drugs may also be used interchangeably at different stages of treatment or under different circumstances to achieve better therapeutic effects.

In general, fruquintinib and bevacizumab are some advanced anti-cancer drugs, but their use needs to be selected according to the specific conditions of the patient. Patients should fully communicate with their doctors to understand the pros and cons of treatment options so that they can make more informed treatment decisions. The doctor will develop the most appropriate treatment plan based on the patient's overall condition and cancer characteristics to achieve the best treatment effect.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.